BNTX
PUTS ▼BioNTech SE
$96.69
-2.20%delayed
News – · Trend ▼ · below put trigger ▼
Expected move (1d)
▼ $92.75to$100.63 ▲
ATR ±$3.94 (+4.08%)Implied ±$3.86 (+3.99%)
Entry Reference
Price / prev close$96.69 / $98.86
Day range$95.80 – $97.66
52-wk range$79.52 – $124.00(39%)
Volume vs avg0.49×
ATR (14d)$3.94
MA 8 / 21$99.01 / $103.68
MA 50 / 200$96.94 / $97.63
Call ▲ / Put ▼ trigger$99.79 / $97.93
+1 / +2 ATR$100.63 / $104.58
-1 / -2 ATR$92.75 / $88.80
Support: 94.41 93.90 93.25
Resistance: 97.44 98.80 113.26
Near-the-money contracts
exp 2026-09-18Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 90 | $6.85 | 0% | 1.00 | -0.01 | 0 |
| 92.5 | $6.19 | 0% | 1.00 | -0.01 | 0 |
| 95 | $3.19 | 0% | 1.00 | -0.01 | 0 |
| 97.5 | $1.73 | 3% | 0.00 | -0.00 | 0 |
| 100 | $0.50 | 13% | 0.00 | -0.00 | 0 |
| 105 | $0.15 | 25% | 0.00 | -0.00 | 0 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 90 | $0.08 | 25% | -0.00 | -0.00 | 0 |
| 92.5 | $0.55 | 13% | -0.00 | -0.00 | 0 |
| 95 | $1.00 | 6% | -0.00 | -0.00 | 0 |
| 97.5 | $2.13 | 0% | -1.00 | 0.01 | 0 |
| 100 | $3.55 | 0% | -1.00 | 0.01 | 0 |
| 105 | $8.40 | 0% | -1.00 | 0.01 | 0 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough14h ago
- Why Is BioNTech Stock Gaining Monday?2d ago
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients2d ago
- Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat5d ago
- 10 Health Care Stocks With Whale Alerts In Today’s Session5d ago
- Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?7d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.